Estimated Time
0.50 hour
Release Date
Feb 02, 2023
Expiration Date
Feb 08, 2024
Activity Description
Despite treatment advances, most patients with multiple myeloma will progress after administration to the standard of care regimens, including proteasome inhibitors, immunomodulatory agents, and chemotherapy. Therefore, it is important for the continual development of novel and effective therapies, especially for underserved communities. Agents targeting B-cell maturation antigen (BCMA) have shown substantial therapeutic responses. Join us in the 2nd episode of the 3-part Med Table Talk® on Navigating the Evidence: Pathways for New and Emerging BCMA Therapies as our expert faculty discuss the safety and efficacy of the emerging BCMA agents. In addition, don’t miss out on the featured conversation with Dr. Saad Usmani, MD, as he discusses practical strategies to improve diversity in clinical trial enrollment.
Speakers
Paula Rodríguez Otero, MD, PhD
Consultant in Hematology
Clínica Universidad de Navarra
Pamplona, Spain
Dr Paula Rodríguez Otero is a member of the Myeloma Unit at the Department of Haematology of the University Hospital of Navarra in Pamplona, Spain, where she has led the clinical trials and immunotherapy programme since 2011, under the direction of Professor Jesus San Miguel. She studied medicine at the University of Navarra, Pamplona, Spain, completed her residency training in haematology at the University Hospital of Navarra, and joined the Faculty of Medicine at the same institution in 2011. From 2009 until 2011, after completing her PhD, she undertook a clinical fellowship in the Bone Marrow Transplant Division at the Hôpital Saint-Louis in Paris, France.
Dr Rodríguez Otero’s research interests include the management, treatment and biology of multiple myeloma, and new immunotherapy strategies. She has collaborated in more than 20 oncology/haematology clinical trials and several translational research projects focused on molecular biology and complications of allogeneic transplantation.
Dr Rodríguez Otero has published articles in high-impact haematology journals and has presented at national and international congresses.
Adrienne A. Phillips, MD, MPH
Associate Professor of Clinical Medicine
Associate Fellowship Program Director Department of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY
Dr. Adrienne A. Phillips graduated from Brown University with a bachelor’s degree in human biology and Latin American studies and a medical degree with honors. She holds a master’s of public health degree from Harvard University. She then came to New York City where she received both her internal medicine training and her fellowship in Hematology/Oncology at New York Presbyterian Hospital-Columbia University Medical Center. She is now an Associate Professor of Clinical Medicine at New York Presbyterian Hospital- Weill Cornell Medicine.
Dr. Phillips has a particular interest in cancer disparities and outcomes among under-served populations, including Caribbean-Americans. She has developed a large database of a rare blood cancer called Adult T-cell Leukemia/Lymphoma, a disease disproportionately seen among Caribbean and Latin-American emigrants. She is the principal investigator of several clinical trials that explore novel therapies for this disease. Her research has been presented at national and international conferences and she has co-authored numerous publications. Dr. Phillips is a member of the American Society of Clinical Oncology, the American Society of Hematology, and the National Medical Association. She is on the editorial board of Leukemia and Lymphoma and she is board certified in internal medicine, hematology, and medical oncology. She has also served as an oncology consultant in Africa and the Caribbean and has a number of international collaborations to address cancer management strategies for developing nations. In recognition of her achievements, she is the recipient of numerous awards including the American Society of Hematology’s prestigious Harold Amos Medical Faculty Career Development Award and The Network Journal’s “40 Under 40” Achievement Award.
Melody Smith, MD, MS
Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA
Dr. Melody Smith received her MD with Distinction in Research from the University of Texas Southwestern Medical School in Dallas. She also completed an internship and residency in Internal Medicine at the University Texas Southwestern. She subsequently moved to Memorial
Sloan Kettering Cancer Center (MSK) to complete her fellowship in Hematology & Medical Oncology. She joined the faculty at MSK in 2015 as an Instructor of Medicine on the Adult Bone Marrow Transplant Service, and she was promoted to Assistant Member Level 1 in 2017.
During her time as junior faculty at MSK, she obtained a Master of Science from Weill Cornell Graduate School of Medical Sciences in Clinical & Translational Investigation. She performed her post-doctoral research in the lab of Marcel van den Brink, MD, PhD and she was co-mentored by Michel Sadelain, MD, PhD.
In September 2021, she joined the faculty at Stanford University as an Assistant Professor in the Division of Blood and Marrow Transplantation and Cellular Therapy in the Department of Medicine to establish her independent lab. As a physician-scientist, her independent research in
the lab focuses on strategies to develop cellular immunotherapy from allogeneic as opposed to autologous sources. She also investigates the regulatory mechanisms for the impact of the intestinal microbiome on chimeric antigen receptor (CAR) T cell outcomes.
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Member, Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY
Dr. Saad Zafar Usmani received his medical education at Allama Iqbal Medical College in Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. He then joined the Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences in Little Rock, AR in 2010 as the Director of Developmental Therapeutics and Assistant Professor of Medicine. He was recruited to the Levine Cancer Institute/Atrium Health in 2013 as the inaugural Division Chief of Plasma Cell Disorders and Director of Clinical Research for Hematologic Malignancies where he built an internationally renowned myeloma program. He now serves as the Chief of Myeloma Service at MSKCC.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and he is a Fellow of the American College of Physicians. He holds membership and leadership roles on national/international committees, including the International Myeloma Working Group, the ALLIANCE Myeloma Committee (Chair), the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the American Society of Transplant & Cellular Therapy, and the National Cancer Institute Myeloma Steering Committee. Dr. Usmani has served as the Vice-Chair of the SWOG Myeloma Committee, and has served as chair for the ASH Scientific Committee on Plasma Cell Neoplasia, and the ASCO Scientific Committee on Plasma Cell Disorders. He has received several international awards recognizing his clinical and translational research contributions to the field, including the Celgene Young Investigator Award for Clinical Research, COMY Award for Excellence in Myeloma Research, LLS Scholar in Clinical Research, the International Myeloma Society Bart Barlogie Award for Clinical and Translational Research, and the LLS CDP Achievement Award. Dr. Usmani has authored/co-authored more than 230 peer-reviewed research manuscripts and over 300 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani has research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Accreditation and Disclosure Information
Target Audience
This activity is intended for hematologic oncologists, physician associates, nurses, and pharmacists who provide care for individuals with Relapsed or Refractory Multiple Myeloma (RRMM).
Educational Objectives
After completing this activity, the participant should be better able to:
- Differentiate the mechanisms of drug resistance/loss of response for emerging BCMA-targeted approaches
- Evaluate the clinical implications of emerging safety and efficacy data for novel BCMA-directed therapies
- Create strategies to improve diversity in clinical trial enrollment and access to care
Program Agenda
- Welcome
- Drug resistance mechanisms using standard first-line regimens
- Efficacy and safety of emerging BCMA-directed therapies
- Strategies to promote timely initiation of care for underrepresented communicates, increase clinical trial enrollment, and advocate for access to care
- Review of key points
- Wrap-up
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour and 0.5 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-23-007-H01-P
Type of Activity: Knowledge
AAPA Credit Designation Statement
Medical Learning Institute, Inc. has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until February 8, 2024. PAs should only claim credit commensurate with the extent of their participation.
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Support Statement
This activity is supported by educational grants from Pfizer, Bristol Myers Squibb, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure & Conflict of Interest Policy
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
Paula Rodríguez Otero, MD, PhD
Consultant in Hematology
Clínica Universidad de Navarra
Pamplona, Spain
Paula Rodríguez Otero, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: AbbVie, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Pfizer, Sanofi
Speakers’ Bureau: Amgen, Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Regeneron, Sanofi
Planner/Presenter
Adrienne A. Phillips, MD, MPH
Associate Professor of Clinical Medicine
Associate Fellowship Program Director
Department of Medicine
Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, NY
Adrienne A. Phillips, MD, MPH, has no relevant financial relationship(s) with ineligible companies to disclose for this educational activity.
Planner/Presenter
Melody Smith, MD, MS
Assistant Professor of Medicine
Stanford University, Department of Medicine
Division of Blood & Marrow Transplantation and Cellular Therapy
Stanford, CA
Melody Smith, MD, MS, has a financial interest/relationship or affiliation in the form of:
Advisory Board/Consultant: Bristol Myers Squibb
Planner/Presenter
Saad Z. Usmani, MD, MBA, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Attending Physician, Myeloma, Cellular Therapy and Adult BMT Services
New York, NY
Saad Z. Usmani, MD, MBA, FACP, has a financial interest/relationship or affiliation in the form of:
Research Grant: Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda
Advisory Board/Consultant: Abbvie, Amgen, Bristol Myers Squibb, Celgene, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute, Inc., the accredited provider, do not have any relevant financial relationship(s) to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute, Inc.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org.
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
About This Activity
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters.
Copyright © 2023 Medical Learning Institute, Inc. All Rights Reserved.